Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
Nimustine (50 μM; 72-120 h) induces apoptosis in cells, which results in cell death[1]. The DNA damage response system is activated by nimomycin (50 μM; 24-96 h)[1]. In glioma cells, nimustine (50 μM; 24-120 h) stimulates MAPK signaling[1].
|
---|---|
ln Vivo |
Nimustine efficiently slows tumor growth, with the higher dose being more effective[2]. Nimustine should be taken 15 times per week or 30 mg/kg twice with a two-week interval.
|
Cell Assay |
Apoptosis Analysis[1]
Cell Types: LN-229 cell line Tested Concentrations: 50 μM Incubation Duration: 72-120 hrs (hours) Experimental Results: Time-dependently induced apoptosis. Western Blot Analysis[1] Cell Types: LN-229 and glioma cell lines Tested Concentrations: 50 μM Incubation Duration: 24-120 hrs (hours) Experimental Results: Induced cleavage of caspase-8 and -9 and the effector caspase-3. Increased phosphorylation of ERK kinase and H2AX. |
Animal Protocol |
Animal/Disease Models: Female C3H/HeN mice with solid FM3A tumors[2]
Doses: 15 and 30 mg/kg Route of Administration: intravenous (iv)injection; 15 (4 times a week) and 30 mg/kg (twice with an interval of 2 weeks) Experimental Results: The intermittent large-dose injections resulted in better inhibition of tumor growth than did the fractionated small-dose injections. |
References |
[1]. Tomicic MT, et al. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget. 2015 Oct 20;6(32):33755-68.
[2]. Shimizu F, et al. Effects of combined treatment with nimustine hydrochloride and radiation on solid FM3A tumor in mice. Jpn J Cancer Res. 1987 Jul;78(7):756-62. |
Molecular Formula |
C9H13CLN6O2
|
---|---|
Molecular Weight |
272.69
|
CAS # |
42471-28-3
|
Related CAS # |
Nimustine hydrochloride;55661-38-6
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CC1=NC=C(C(N1)=N)CNC(N(N=O)CCCl)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6672 mL | 18.3358 mL | 36.6717 mL | |
5 mM | 0.7334 mL | 3.6672 mL | 7.3343 mL | |
10 mM | 0.3667 mL | 1.8336 mL | 3.6672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.